Literature DB >> 19383857

Relation of exhaled nitric oxide levels to development of bronchopulmonary dysplasia.

C May1, O Williams, A D Milner, J Peacock, G F Rafferty, S Hannam, A Greenough.   

Abstract

OBJECTIVE: To test the hypothesis that exhaled nitric oxide levels on day 28 and changes in exhaled nitric oxide levels in the neonatal period would differ according to whether infants developed bronchopulmonary dysplasia (BPD) and its severity.
DESIGN: Prospective observational study.
SETTING: Tertiary neonatal intensive care unit. PATIENTS: 80 infants (median gestational age 28, range 24-32 weeks), 46 of whom developed BPD.
INTERVENTIONS: Exhaled nitric oxide measurements were attempted on days 3, 5, 7, 14, 21 and 28. MAIN OUTCOME MEASURES: BPD (oxygen dependency at 28 days), mild BPD (oxygen dependent at 28 days, but not 36 weeks postmenstrual age (PMA)); moderate BPD (oxygen dependent at 36 weeks PMA) and severe BPD (respiratory support dependent at 36 weeks PMA).
RESULTS: On day 28, exhaled nitric oxide levels were higher in infants with BPD compared to those without BPD (p<0.001) and there was a linear trend in exhaled nitric oxide results as BPD severity increased (p = 0.006). No significances in the change in exhaled nitric oxide levels over the neonatal period were found between the four groups.
CONCLUSION: Exhaled nitric oxide levels are raised in infants with established BPD, particularly in those developing moderate or severe BPD, and may reflect ongoing inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383857     DOI: 10.1136/adc.2008.146589

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  10 in total

1.  Development of severe bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds.

Authors:  Daniel J C Berkhout; Hendrik J Niemarkt; Marc A Benninga; Andries E Budding; Anton H van Kaam; Boris W Kramer; Charlene M Pantophlet; Mirjam M van Weissenbruch; Nanne K H de Boer; Tim G J de Meij
Journal:  Pediatr Res       Date:  2017-11-22       Impact factor: 3.756

Review 2.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

Review 3.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

Review 4.  Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia.

Authors:  Charitharth Vivek Lal; Namasivayam Ambalavanan
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

5.  Exhaled nitric oxide in neonates with or without hypoxemic respiratory failure.

Authors:  Li-Juan Liu; Xi-Rong Gao; Pan-Pan Wu; Li-Ling Qian; Chao Chen; Bo Sun
Journal:  World J Emerg Med       Date:  2011

6.  Anti-inflammatory effects of adrenomedullin on acute lung injury induced by Carrageenan in mice.

Authors:  Elena Talero; Rosanna Di Paola; Emanuela Mazzon; Emanuela Esposito; Virginia Motilva; Salvatore Cuzzocrea
Journal:  Mediators Inflamm       Date:  2012-05-20       Impact factor: 4.711

7.  Effect of intubation and mechanical ventilation on exhaled nitric oxide in preterm infants with and without bronchopulmonary dysplasia measured at a median postmenstrual age of 49 weeks.

Authors:  Gerd Schmalisch; Silke Wilitzki; Hendrik S Fischer; Christoph Bührer
Journal:  BMC Res Notes       Date:  2014-06-24

8.  Cytokines and Exhaled Nitric Oxide Are Risk Factors in Preterm Infants for Bronchopulmonary Dysplasia.

Authors:  Zhenjie Zhang; Wuchen Wu; Lian Hou; Jingjing Jiang; Weilin Wan; Zhenghong Li
Journal:  Biomed Res Int       Date:  2021-01-12       Impact factor: 3.411

9.  Cohort profile: the vitamin A and D and nitric oxide (AD-ON) observational cohort on lung development and symptoms in premature and mature children in North Zealand, Denmark.

Authors:  Fanny Edit Maria Goth; Birgitte Johanne Schmidt; Klaus Juul; Per Albertsen; Lone Agertoft; Inger Merete Jørgensen
Journal:  BMJ Open       Date:  2022-02-22       Impact factor: 2.692

10.  Application of nitric oxide measurements in clinical conditions beyond asthma.

Authors:  Andrei Malinovschi; Dora Ludviksdottir; Ellen Tufvesson; Giovanni Rolla; Leif Bjermer; Kjell Alving; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2015-08-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.